Wayne S. Fenton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wayne S. Fenton has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ellen L. Stover
Behavioral Research and AIDS National Institute of Mental Health, National Institute of Health, US Department of Health and Human Services Room 6217
1 shared publicationEllen S Stover
1 shared publicationFaith Dickerson
1 shared publicationJames M. Herrell
1 shared publication- Jeffrey S. Hoch
Division of Health Policy and Management, Department of Public Health Sciences, University of California, Davis, California
1 shared publication John Boronow
1 shared publication
Latest Publications
- Open Access
- 1 July 2006
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 19 (4) , 421-427
Mood disorders: cardiovascular and diabetes comorbidity
Depression is often associated with medical comorbidity. New research quantifies patterns of mood disorder in illnesses such as cardiovascular disease and diabetes, evaluates the prognostic significance of mood symptoms, and seeks to identify common mechanisms for both mood and medical disease. This review provides recent findings on comorbidity, summarizes mechanistic hypotheses, and outlines developments in treatment and services. Depression occurs in up to one-quarter of patients with cardiovascular disease and diabetes. Depressed patients with heart disease have poorer medical outcomes including increased risk of reinfarction and all-cause mortality. Patients with diabetes and depression have poorer glycemic control, more diabetes symptoms, and greater all-cause mortality. Depression is associated with both biological (hypothalamic-pituitary-adrenal axis dysregulation) and psychosocial processes (adherence, poorer diet, and exercise) that may mediate adverse medical outcomes. Antidepressant treatments are effective in treating depression in medically ill patients, but their impact on medical outcomes remains to be quantified. Depression, cardiovascular disease, and diabetes are among the most common chronic illnesses affecting an aging population. Depression is treatable in patients with medical illnesses, and collaborative care models can yield better detection and depression treatment in primary care settings in which most patients with depression are seen.
- 1 July 2006
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 19 (4) , 421-427
Open AccessMood disorders: cardiovascular and diabetes comorbidity
Depression is often associated with medical comorbidity. New research quantifies patterns of mood disorder in illnesses such as cardiovascular disease and diabetes, evaluates the prognostic significance of mood symptoms, and seeks to identify common mechanisms for both mood and medical disease. This review provides recent findings on comorbidity, summarizes mechanistic hypotheses, and outlines developments in treatment and services. Depression occurs in up to one-quarter of patients with cardiovascular disease and diabetes. Depressed patients with heart disease have poorer medical outcomes including increased risk of reinfarction and all-cause mortality. Patients with diabetes and depression have poorer glycemic control, more diabetes symptoms, and greater all-cause mortality. Depression is associated with both biological (hypothalamic-pituitary-adrenal axis dysregulation) and psychosocial processes (adherence, poorer diet, and exercise) that may mediate adverse medical outcomes. Antidepressant treatments are effective in treating depression in medically ill patients, but their impact on medical outcomes remains to be quantified. Depression, cardiovascular disease, and diabetes are among the most common chronic illnesses affecting an aging population. Depression is treatable in patients with medical illnesses, and collaborative care models can yield better detection and depression treatment in primary care settings in which most patients with depression are seen.
- 1 December 2004
- Published by Springer Nature in Academic Psychiatry
- Vol. 28 (4) , 263-266
Psychiatry Residency Training, the Physician-Scientist, and the Future of Psychiatry
- 1 December 2004
- Published by Springer Nature in Academic Psychiatry
- Vol. 28 (4) , 263-266
Psychiatry Residency Training, the Physician-Scientist, and the Future of Psychiatry
- 1 September 2003
- Published by Springer Nature in Psychopharmacology
- Vol. 169 (3-4) , 365-366
Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective
- 1 September 2003
- Published by Springer Nature in Psychopharmacology
- Vol. 169 (3-4) , 365-366
Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective
- Open Access
- 1 April 2002
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 59 (4) , 357-364
Cost and Cost-effectiveness of Hospital vs Residential Crisis Care for Patients Who Have Serious Mental Illness
MOST PATIENTS with severe mental illness are treated in community settings, where programs charged with caring for them operate under tight fiscal constraints.1,2 Economic studies of these programs point to acute care episodes involving hospitalization as the single largest cost element in the array of services needed to provide community care.3-5 In psychiatry, as in the rest of medicine, limiting use of costly inpatient services has been a major strategy for controlling costs.6,7 Concurrently, limitations in services, including acute care services with very limited lengths of stay, are widely perceived as placing serious burdens on the patients, community mental health systems, and the society that must absorb and manage the consequences of inadequately treated mental illness.8-10
- 1 April 2002
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 59 (4) , 357-364
Open AccessCost and Cost-effectiveness of Hospital vs Residential Crisis Care for Patients Who Have Serious Mental Illness
MOST PATIENTS with severe mental illness are treated in community settings, where programs charged with caring for them operate under tight fiscal constraints.1,2 Economic studies of these programs point to acute care episodes involving hospitalization as the single largest cost element in the array of services needed to provide community care.3-5 In psychiatry, as in the rest of medicine, limiting use of costly inpatient services has been a major strategy for controlling costs.6,7 Concurrently, limitations in services, including acute care services with very limited lengths of stay, are widely perceived as placing serious burdens on the patients, community mental health systems, and the society that must absorb and manage the consequences of inadequately treated mental illness.8-10
- 1 December 2001
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (12) , 2071-2074
A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia
OBJECTIVE: This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder. METHOD: Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial. Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16. RESULTS: No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings. Results were similar for the intention-to-treat (N=87) and completer (N=75) groups. CONCLUSIONS: For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia ...
- 1 December 2001
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (12) , 2071-2074
A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia
OBJECTIVE: This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder. METHOD: Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial. Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16. RESULTS: No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings. Results were similar for the intention-to-treat (N=87) and completer (N=75) groups. CONCLUSIONS: For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia ...